That regulatory shift moved the hard work upstream, to feasibility. This is the stage where sponsors test whether a protocol can actually be executed: Are there enough eligible children? Will caregivers say yes? Can sites deliver quality data without overburdening a child?
This article breaks down what makes pediatric feasibility different, what site readiness really requires, how recruitment strategies need to shift, and where a research partner with multi-regional experience makes a measurable difference.
Key Takeaways
- Pediatric feasibility must account for developmental, ethical, and logistical factors adult trials never face
- Site readiness depends on pediatric-trained staff, child-friendly spaces, and realistic capacity for slow enrollment
- Recruitment success hinges on caregiver trust, flexible scheduling, and minimal procedural burden
- A CRO with multi-regional pediatric experience can shorten timelines and reach more diverse populations
What Is Feasibility in Pediatric Clinical Trials?
Feasibility assessment is the pre-trial exercise of determining whether a site, patient population, and protocol design can realistically hit enrollment and data-quality targets. It's the reality check before a protocol gets locked.
In adult trials, feasibility is largely a numbers game: patient volume, competing studies, site throughput. Pediatric feasibility adds several layers:
- Smaller eligible populations — many pediatric conditions affect a fraction of the patients seen in adult indications
- Parental/guardian gatekeeping — no child enrolls without a parent saying yes, adding a second decision-maker to every recruitment conversation
- Stricter ethical review — IRBs apply additional protections under federal regulations specific to children
The scale of the problem shows up in the literature. A review of 736 pediatric medication trials published between 1996 and 2002 found that only 38% enrolled more than 100 participants (Sammons and Choonara, 2005). Small samples aren't the exception in pediatric research. They're closer to the norm, which makes every feasibility decision higher stakes.
Unique Challenges in Site Readiness
Not every clinical site that runs adult trials well can pivot to pediatric research. Readiness looks different for children.
Pediatric-Specific Infrastructure and Equipment
Sites need equipment and spaces built for children, not scaled-down adult setups:
- Age- and size-appropriate blood pressure cuffs and smaller-volume phlebotomy supplies
- Exam rooms that feel less clinical and cold
- Waiting areas with age-appropriate distractions instead of adult-only signage
A waiting room designed only for adults can raise a child's anxiety before the visit even starts.
Staffing With Pediatric Expertise
Coordinators and phlebotomists with pediatric experience shape procedure efficiency and how much distress a child experiences. A 2022 study found that when Child Life Specialists facilitated play during blood draws, median procedure time dropped from 5 minutes to 3 minutes, and fear scores of 3-4 fell from 38.7% to 17.3% (Getchell et al., 2022).
Rather than building standalone research sites, embedding trained research staff within existing pediatric practices often works better. Families already trust their pediatrician's office. That trust doesn't automatically transfer to an unfamiliar research facility across town.
Minimizing Procedural Burden
Protocol design should reflect published blood-volume guidance, which generally caps sampling around 3% of estimated circulating blood volume over a 2- to 8-week period (Joseph et al., 2015). Shorter visit windows and fewer draws are easier on families and lower dropout risk.
Trust as a Site Selection Criterion
When ranking sites, treat existing pediatric care relationships as a selection requirement, not a soft preference. Enrollment and retention track closely with whether families already know the clinicians involved. A recommendation from the child's own physician consistently outperforms cold outreach.
Site Capacity for Flexible Scheduling
Children have school. Parents have jobs. Site readiness has to include:
- Early morning or evening appointment slots
- Weekend availability
- Split-visit options that break longer assessments into shorter sessions
Feasibility Data Gathering for Site Selection
Before activating a site, sponsors and CROs should review:
- Historical pediatric enrollment performance — has the site hit targets on past pediatric studies?
- Therapeutic area experience — does staff understand the specific condition and its pediatric population?
- Discontinuation rates — what caused past withdrawals, and can those causes be addressed in this protocol?
Recruitment Challenges and Strategies in Pediatric Trials
Pediatric enrollment stalls for a handful of repeatable reasons: caregiver and investigator hesitation, dual-audience communication, family logistics, early discontinuation, and thin eligible populations. Each needs a targeted response.
Overcoming Caregiver and Investigator Reluctance
Placebo assignment is a leading barrier. A 2024 overview of systematic reviews found median parental consent rates of 72% for placebo-controlled studies versus 87% when an active comparator was used (Bencheva et al., 2024). Transparent, plain-language risk-benefit conversations close that gap more than any brochure can.
Investigators hesitate as well, often over protocol complexity, perceived patient risk, and limited pediatric trial experience. Early site engagement and clear safety-monitoring plans reduce that friction.
Communicating Across Two Audiences
Every pediatric trial requires two parallel conversations: detailed risk-benefit discussion with parents, and age-appropriate assent language for the child. A 7-year-old and a 15-year-old need entirely different explanations of what "participating in a study" actually means.
Reducing Logistical Barriers to Participation
Travel distance, missed school, missed work, and childcare for siblings all chip away at enrollment. Decentralized elements can offset some of this burden, particularly for families in rural or underserved areas (Paternuosto et al., 2025):
- Home visits for assessments and sample collection
- Telemedicine check-ins in place of routine site visits
- Wearable and remote data collection between visits
Addressing High Discontinuation Rates
Discontinuation isn't rare in pediatric research. A registry study of 559 pediatric randomized trials found 19% discontinued early, with difficulty in patient accrual cited as the reason in 37% of cases (Pica and Bourgeois, 2016). Complex protocols, higher costs, and small eligible populations compound the problem, especially for vulnerable groups where additional safeguards slow enrollment further.
Leveraging Multinational Networks to Pool Rare Populations
For rare diseases and pediatric oncology, no single country typically has enough eligible patients. Multi-regional collaboration and specialist pediatric networks pool small populations across borders, turning an unfeasible single-site study into a viable multinational one.
Regulatory Landscape for Pediatric Trials
The FDA framework rests on three pillars:
- PREA — requires pediatric studies for certain new drugs and biologics
- BPCA — offers pediatric exclusivity incentives through a Written Request process
- iPSP — the initial Pediatric Study Plan, generally due within 60 days of the end-of-phase 2 meeting
In the EU, sponsors submit a Pediatric Investigation Plan (PIP), reviewed by EMA's Paediatric Committee.
For ethics review, IRBs apply 45 CFR 46 Subpart D, requiring parental permission alongside child assent. Assent is typically sought starting around age 7 in US practice, though this is an institutional norm rather than a strict federal age cutoff. IRBs weigh the child's maturity and psychological state.
Feasibility planning has to account for these submissions early. A delayed iPSP or PIP can stall site activation by months, no matter how ready the sites themselves are.
How a Global CRO Partner Strengthens Pediatric Feasibility
Pediatric feasibility grows more complex when a trial spans multiple countries with different healthcare systems, consent norms, and eligible population sizes. A CRO with multi-regional experience and localized proficiency can identify feasible sites sponsors might otherwise overlook, including underserved populations often left out of trial planning.
DRK Research Solutions has built its operating model around this kind of reach. The company operates across Switzerland, the UK, the USA, Pakistan, Malaysia, Nepal, the UAE, and Bangladesh.
DRK's roots as a patient advocacy organization shaped a patient-centric approach focused on expanding access to modern treatments across low- and middle-income countries. That history matters for pediatric feasibility, where trust, access, and local relationships often determine whether a study succeeds.
DRK keeps site identification, feasibility, and recruitment support in one coordinated workflow with:
- Protocol design support
- Regulatory submissions
- Trial monitoring
- Clinical data management
Combining these functions under one team cuts the handoff delays that slow pediatric study start-up.
Frequently Asked Questions
What is feasibility in pediatric clinical trials?
Feasibility is the pre-trial process of evaluating whether sites, patient populations, and protocol design can realistically achieve enrollment and data-quality targets for a study involving children.
What are the FDA guidelines for pediatric clinical trials?
FDA oversight centers on the Pediatric Research Equity Act (PREA), which mandates pediatric studies for certain drugs; the Best Pharmaceuticals for Children Act (BPCA), which offers exclusivity incentives; and the initial Pediatric Study Plan (iPSP) sponsors must file early in development.
What are recent advances in pediatric clinical trials?
Sponsors are adopting decentralized elements like telemedicine and home visits, minimally invasive methods such as dried-blood-spot microsampling, and engagement tools like gamified apps to cut participant burden and improve enrollment.
How is informed consent handled differently in pediatric trials?
Parents or guardians provide informed consent, while children give age-appropriate assent based on developmental maturity. US regulations require both before a child can enroll.
Why do pediatric trials have higher discontinuation rates than adult trials?
Small eligible populations, protocol complexity, higher costs, and extra ethical safeguards for a vulnerable population all make pediatric trials more prone to early discontinuation than adult studies.
What makes a clinical trial site "ready" for pediatric research?
A ready site has pediatric-trained staff, age-appropriate equipment and spaces, and the scheduling flexibility to work around school and family commitments.
